China approves BTG's DC Bead

BTG plc (LSE:BTG) and SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) said the China Food and Drug Administration (CFDA) approved BTG's DC Bead to treat patients with malignant hypervascularized tumors like hepatocellular carcinoma (HCC). DC Bead is a drug-eluting bead for controlled release of doxorubicin or irinotecan. SciClone has exclusive Chinese commercialization rights to the product. ...